Conventional type 1 dendritic cells in protective antitumor immunity and its potential in hepatocellular carcinoma

• 作者: Chunfeng Qu Kun Chen Shao-Yan Cheng
• 来源期刊: 肝癌研究（英文版）
• 年，卷（期）: 2020,（7）
• 所属期刊栏目: Review
• 页码范围: 14-20
• 页数: 7页
• 语种: 英文
• DOI: 10.20517/2394-5079.2020.12

摘要

Immunotherapy is revolutionizing the clinical management of cancer patients by modulating T cells and natural killer cells. Dendritic cells (DCs) have the capacity to orchestrate the expansion and function of these effector cells both in lymphoid and non-lymphoid tissues of cancer patients. Distinct subtypes of DCs have various capacities to prime and activate different T cell responses. Here, we review conventional type 1 dendritic cells (cDC1s) and their crucial role in protective anti-tumor immunity. Targeting cDC1s as a cancer vaccine against the development of hepatocellular carcinoma will be discussed.